The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - MSD (U)
Lin Shen
Research Funding - Roche
Yoon-Koo Kang
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis
Piotr Rutkowski
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Shukui Qin
No relevant relationships to disclose
Dmitry Nosov
No relevant relationships to disclose
Steven C. Novick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Lilia Taningco
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Shuyuan Mo
Employment or Leadership Position - Novartis
Peter Reichardt
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
George D. Demetri
Consultant or Advisory Role - ARIAD; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - GlaxoSmithKline (U); Johnson & Johnson (U); Merck (U)